US EditionValorum Biologics to Commercialize Formycon’s Eylea Biosimilar FYB203 in US and Canada
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Valorum Biologics to commercialize Formycon’s Eylea Biosimilar FYB203 in US and Canada
FYB203 has been approved by the US FDA and UK Medicines and Healthcare products Regulatory Agency for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema, macular edema following retinal vein occlusion, and visual impairment due to myopic choroidal neovascularization.
Valorum Biologics Becomes Commercialization Partner for Formycon’s Eylea Biosimilar FYB203/AHZANTIVE (aflibercept-mrbb) in the United States and Canada
Formycon announced that Klinge Biopharma, the exclusive owner of the global commercialization rights of FYB203/AHZANTIVE (aflibercept-mrbb), Formycon’s biosimilar to Eylea, concluded an exclusive license agreement with US biosimilars specialist Valorum Biologics for the commercialization of FYB203/AHZANTIVE in the United States and Canada. Upon signature of the agreement, Klinge is eligible to receive upfront payments and milestone payments, plu…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
